Mast cells and mast cell mediators as targets of dietary supplements

Annals of Allergy, Asthma and Immunology

Volumn 93, Issue 2 SUPPL. 1, 2004, Pages

  Theoharides, Theoharis C ^a   Bielory, Leonard ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; ECHINACEA EXTRACT; EPHEDRA EXTRACT; EUCALYPTUS EXTRACT; FLAVONOID; GLUCOSAMINE SULFATE; HEPARIN; HISTAMINE; IMMUNOGLOBULIN E; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MINERAL; PEPPERMINT OIL; PLANT EXTRACT; PROTEOGLYCAN; QUERCETIN; SALVIA MILTIORRHIZA EXTRACT; SHO SEIRYU TO; TUMOR NECROSIS FACTOR ALPHA; UROCORTIN; URTICA DIOICA EXTRACT; VITAMIN;

ACUTE HEPATITIS; ALLERGIC RHINITIS; ALLERGY; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARISTOLOCHIA; ARTHRITIS; CHOLESTATIC HEPATITIS; CHRONIC INFLAMMATION; CONFERENCE PAPER; CYSTITIS; DIET SUPPLEMENTATION; DRUG SAFETY; HEART ARRHYTHMIA; HISTAMINE RELEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KNOCKOUT MOUSE; MAST CELL; MEDIATOR RELEASE; MEDLINE; MOUSE; NEPHROLITHIASIS; NONHUMAN; PELVIS PAIN SYNDROME; PETASITES; PRIORITY JOURNAL; PROSTATITIS; QUALITY OF LIFE; STROKE; SUDDEN DEATH; SYSTEMATIC REVIEW;

EID: 4344635570     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61484-6     Document Type: Conference Paper

References (158)

1. Bielory L. Complementary medicine for the allergist. Allergy Asthma Proc. 2001;22:33-37.
2. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med. 1993;328:246-252.
3. Blanc PD, Trupin L, Earnest G, Katz PP, Yelin EH, Eisner MD. Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis: data from a population-based survey. Chest. 2001;120:1461-1467.
4. Bielory L. Complementary/alternative medicine: we need to become more knowledgeable. Ann Allergy Asthma Immunol. 2000;85:427-428.
5. Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology. 2001;57:47-55.
6. Theoharides TC, Sant GR. New agents for the medical treatment of interstitial cystitis. Exp Opin Invest Drugs. 2001;10:527-552.
7. Bielory L. Replacing myth and prejudice with scientific facts about complementary and alternative medicine. Ann Allergy Asthma Immunol. 2002;249-250.
8. Galli SJ. New concepts about the mast cell. N Engl J Med. 1993;328:257-265.
9. Rosenwasser LJ, Boyce JA. Mast cells: beyond IgE. J Allergy Clin Immunol. 2003;111:24-32.
10. Schwartz LB. Mediators of human mast cells and human mast cell subsets. Ann Allergy. 1987;58:226-235.
11. Serafin WE, Austen KF. Mediators of immediate hypersensitivity reactions. N Engl J Med. 1987;317:30-34.
12. Kobayashi H, Ishizuka T, Okayama Y. Human mast cells and basophils as sources of cytokines. Clin Exp Allergy. 2000;30:1205-1212.
13. Marone G, Galli SJ, Kitamura Y. Probing the roles of mast cells and basophils in natural and acquired immunity, physiology and disease. Trends Immunol. 2002;23:425-427.
14. Theoharides TC. The mast cell: a neuroimmunoendocrine master player. Int J Tissue React. 1996;18:1-21.
15. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol. 2004;146:1-12.
16. Maurer M, Theoharides TC, Granstein RD, et al. What is the physiological function of mast cells? Exp Dermatol. 2003;12:886-910.
17. Tetlow LC, Woolley DE. Distribution, activation and tryptase/ chymase phenotype of mast cells in the rheumatoid lesion. Ann Rheum Dis. 1995;54:549-555.
18. Wasserman SI. The mast cell and synovial inflammation. Arthritis Rheum. 1984;27:841-844.
19. Theoharides TC. Mast cell and stress: a psychoneuroimmunological perspective J Clin Psychopharmacol. 2002;22:103-108.
20. Theoharides TC, Bondy PK, Tsakalos ND, Askenase PW. Differential release of serotonin and histamine from mast cells. Nature. 1982;297:229-231.
21. Dvorak AM, MacGlashan DW Jr, Morgan ES, Lichtenstein LM. Vesicular transport of histamine in stimulated human basophils. Blood. 1996;88:4090-4101.
22. Benyon R, Robinson C, Church MK. Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. Br J Pharmacol. 1989;97:898-904.
23. Gagari E, Tsai M, Lantz CS, Fox LG, Galli SJ. Differential release of mast cell interleukin-6 via c-kit. Blood. 1997;89:2654-2663.
24. Kandere-Grzybowska K, Letourneau R, Boucher W, et al. IL- 1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol. 2003;171:4830-4836.
25. Kraeuter Kops S, Theoharides TC, Cronin CT, Kashgarian MG, Askenase PW. Ultrastructural characteristics of rat peritoneal mast cells undergoing differential release of serotonin without histamine and without degranulation. Cell Tissue Res. 1990;262:415-424.
26. Dvorak AM, Tepper RI, Weller PF, et al. Piecemeal degranulation of mast cells in the inflammatory eyelid lesions of interleukin-4 transgenic mice. Evidence of mast cell histamine release in vivo by diamine oxidase-gold enzyme-affinity ultrastructural cytochemistry. Blood. 1994;83:3600-3612.
27. Letourneau R, Pang X, Sant GR, Theoharides TC. Intragranular activation of bladder mast cells and their association with nerve processes in interstitial cystitis. Br J Urol. 1996;77:41-54.
28. Katsarou-Katsari A, Filippou A, Theoharides TC. Effect of stress and other psychological factors on the pathophysiology and treatment of dermatoses. Int J Immunopathol Pharmacol. 1999;12:7-11.
29. Slominski AT, Botchkarev V, Choudhry M, et al. Cutaneous expression of CRH and CRH-R: is there a "skin stress response system?" Ann NY Acad Sci. 1999;885:287-311.
30. Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev. 2000;80:979-1020.
31. Katsarou-Katsari A, Singh LK, Theoharides TC. Alopecia areata and affected skin CRH receptor upregulation induced by acute emotional stress. Dermatology. 2001;203:157-161.
32. Lytinas M, Kempuraj D, Huang M, Boucher W, Esposito P, Theoharides TC. Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists. Int Arch Allergy Immunol. 2003;130:224-231.
33. Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC. Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin and substance P: a link to neurogenic skin disorders. Brain Behav Immunol. 1999;13:225-239.
34. Theoharides TC, Singh LK, Boucher W, et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its pro-inflammatory effects. Endocrinology. 1998;139:403-413.
35. Singh LK, Boucher W, Pang X, et al. Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of CRH receptors. J Pharmacol Exp Ther. 1999;288:1349-1356.
36. McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol. 2003;170:1625-1629.
37. Barke KE, Hough LB. Opiates, mast cells and histamine release. Life Sci. 1993;53:1391-1399.
38. Di Lorenzo G, Pacor ML, Vignola AM, et al. Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria patients. Allergy. 2002;57:1180-1186.
39. Lagunoff D, Martin TW, Read G. Agents that release histamine from mast cells. Annu Rev Pharmacol Toxicol. 1983;23:331-351.
40. Swain AR, Dutton SP. Salicylates in foods. J Am Diet Assoc. 1985;85:950-959.
41. Janssen PL, Katan MB, van Staveren WA, Hollman PC, Venema DP. Acetylsalicylate and salicylates in foods. Cancer Lett. 1997;114:163-164.
42. Theoharides TC. Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink. J Clin Psychopharmacol. 1997;17:437-439.
43. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc. 2002;77:12-16.
44. Boucher W, Theoharides TC. Ephedrine augments histamine release from rodent mast cells. Int J Immunopathol Pharmacol. In press.
45. Becker K, Southwick K, Reardon J, Berg R, MacCormack JN. Histamine poisoning associated with eating tuna burgers. JAMA. 2001;285:1327-1330.
46. Lehane L, Olley J. Histamine fish poisoning revisited. Int J Food Microbiol. 2000;58:1-37.
47. Petry JJ, Hadley SK. Medicinal herbs: answers and advice, part 1. Hosp Pract (Off Ed). 2001;36:57-60.
48. Petry JJ, Hadley SK. Medicinal herbs: answers and advice, part 2. Hosp Pract (Off Ed). 2001;36:55-59.
49. Morris CA, Avorn J. Internet marketing of herbal products. JAMA. 2003;290:1505-1509.
50. DeAngelis CD, Fontanarosa PB. Drugs alias dietary supplements. JAMA. 2003;290:1519-1520.
51. Kessler DA. Cancer and herbs. N Engl J Med. 2000;342:1742-1723.
52. Bauer BA. Herbal therapy: what a clinician needs to know to counsel patients effectively. Mayo Clin Proc. 2000;75:835-841.
53. Harnack LJ, Rydell SA, Stang J. Prevalence of use of herbal products by adults in the Minneapolis/St Paul, Minn, metropolitan area. Mayo Clin Proc. 2001;76:688-694.
54. Hensrud DD, Engle DD, Scheitel SM. Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination. Mayo Clin Proc. 1999;74:443-447.
55. Herbert V. Underreporting of dietary supplements to health-care providers does great harm. Mayo Clin Proc. 1999;74:531-532.
56. Niggemann B, Gruber C. Side-effects of complementary and alternative medicine. Allergy. 2003;58:707-716.
57. Steingarten J. Salad: the silent killer. House & Garden. 1988;160:172, 173, 214, 215.
58. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA. 2001;286:208-216.
59. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003;290:1500-1504.
60. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA. 2001;285:1978-1986.
61. Kane GC, Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc. 2000;75:933-942.
62. Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R. Ginkgo for memory enhancement: a randomized controlled trial. JAMA. 2002;288:835-840.
63. Tsubono Y, Nishino Y, Komatsu S, et al. Green tea and the risk of gastric cancer in Japan. N Engl J Med. 2001;344:632-636.
64. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342:1686 -1692.
65. Slattery ML. Does an apple a day keep breast cancer away? JAMA. 2001;285:799-801.
66. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA. 2001;285:769-776.
67. Chlebowski RT. Reducing the risk of breast cancer. N Engl J Med. 2000;343:191-198.
68. Bedry R, Baudrimont I, Deffieux G, et al. Wild-mushroom intoxication as a cause of rhabdomyolysis. N Engl J Med. 2001;345:798-802.
69. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Res. 2000;52:673-751.
70. Theoharides TC, Alexandrakis M, Kempuraj D, Lytinas M. Anti-inflammatory actions of flavonoids and structural requirements for new design. Int J Immunopathol Pharmacol. 2001;14:119-127.
71. Theoharides TC, Patra P, Boucher W, et al. Chondroitin sulfate inhibits connective tissue mast cells. Br J Pharmacol. 2000;131:1039-1049.
72. Ro JY, Lee BC, Kim JY, et al. Inhibitory mechanism of aloe single component (alprogen) on mediator release in guinea pig lung mast cells activated with specific antigen-antibody reactions. J Pharmacol Exp Ther. 2000;292:114-121.
73. Davis RH, Stewart GJ, Bregman PJ. Aloe vera and the inflamed synovial pouch model. J Am Podiatr Med Assoc. 1992;82:140-148.
74. Dembner A. One-third of adults in US have arthritis, according to survey. The Boston Globe. October 25, 2002:A3.
75. Dunlop DD, Manheim LM, Yelin EH, Song J, Chang RW. The costs of arthritis. Arthritis Rheum. 2003;49:101-113.
76. Manek NJ. Medical management of osteoarthritis. Mayo Clin Proc. 2001;76:533-539.
77. Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2000;59:936-944.
78. Walker-Bone K, Javaid K, Arden N, Cooper C. Regular review: medical management of osteoarthritis. BMJ. 2000;321:936-940.
79. Bridges AJ, Malone DG, Jicinsky J, et al. Human synovial mast cell involvement in rheumatoid arthritis and osteoarthritis. Relationship to disease type, clinical activity, and antirheumatic therapy. Arthritis Rheum. 1991;34:1116-1124.
80. Ceponis A, Konttinen YT, Takagi M, et al. Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. J Rheumatol. 1998;25:2304-2314.
81. Crisp AJ, Champan CM, Kirkham SE, Schiller AL, Krane SM. Articular mastocytosis in rheumatoid arthritis. Arthritis Rheum. 1984;27:845-851.
82. de Paulis A, Ciccarelli A, Marinò I, de Crescenzo G, Marino D, Marone G. Human synovial mast cells. II: heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs. Arthritis Rheum. 1997;40:469-478.
83. de Paulis A, Marino I, Ciccarelli A, et al. Human synovial mast cells. I: ultrastructural in situ and in vitro immunologic characterization. Arthritis Rheum. 1996;39:1222-1233.
84. Gotis-Graham I, Smith MD, Parker A, McNeil HP. Synovial mast cell responses during clinical improvement in early rheumatoid arthritis. Ann Rheum Dis. 1998;57:664-671.
85. He S, Gaca MD, Walls AF. The activation of synovial mast cells: modulation of histamine release by tryptase and chymase and their inhibitors. Eur J Pharmacol. 2001;412:223-229.
86. Kiener HP, Baghestanian M, Dominkus M, et al. Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:233-245.
87. Kobayashi Y, Okumishi H. Mast cells as a target of rheumatoid arthritis treatment. Jpn J Pharmacol. 2002;90:7-11.
88. Kim MS, Choi IY, Lee SH, Hong SH, Shin T, Kim HM. The Oriental medicine "cool-cool (Cool-X-A)" inhibits inflammatory cytokine production and migration in mast cells. Biol Pharm Bull. 2004;27:34-37.
89. Olsson N, Ulfgre AK, Nilsson G. Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients. Ann Rheum Dis. 2001;60:187-193.
90. Woolley DE. Mast cells in the rheumatoid lesion: ringleaders or innocent bystanders? Ann Rheum Dis. 1995;54:533-534.
91. Kruger-Krasagakes S, Moller A, Kolde G, Lipper U, Weber M, Henz BM. Production of interleukin-6 by human mast cells and basophilic cells. J Invest Dermatol. 1996;106:75-79.
92. v mice lack stress-induced increase in serum IL-6 levels, as well as in peripheral CRH and vascular permeability, a model of rheumatoid arthritis. Int J Immunopathol Pharmacol. 2002;15:249-254.
93. Keul R, Heinrich PC, Muller-Newen G, Muller K, Woo P. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine. 1998;10:729-734.
94. Pignatti P, Vivarelli M, Meazza C, Rizzolo MG, Martini A, De Benedetti F. Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J Rheumatol. 2001;28:1670-1676.
95. Alonzi T, Fattori E, Lazzaro D, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med. 1998;187:461-468.
96. Ohshima S, Saeki Y, Mima T, et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA. 1998;95:8222-8226.
97. Boe A, Baiocchi M, Carbonatto M, Papoian R, Serlupi-Crescenzi O. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine. 1999;11:1057-1064.
98. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002;297:1689-1692.
99. Mattheos S, Christodoulou S, Kempuraj D, et al. Mast cells and corticotropin-releasing hormone (CRH) are required for experimental inflammatory arthritis. FASEB J. 2003;17:C44.
100. Thomason BT, Brantley PJ, Jones GN, Dyer HR, Morris JL. The relation between stress and disease activity in rheumatoid arthritis. J Behav Med. 1992;15:215-220.
101. Herrmann M, Scholmerich J, Straub RH. Stress and rheumatic diseases. Rheum Dis Clin North Am. 2000;26:737-763.
102. Johnson EO, Moutsopoulos M. Neuroimmunological axis and rheumatic diseases. Eur J Clin Invest. 1992;22:S2-S5.
103. McEvoy AN, Bresnihan B, FitzGerald O, Murphy EP. Corticotropin-releasing hormone signaling in synovial tissue from patients with early inflammatory arthritis is mediated by the type 1 αcorticotropin-releasing hormone receptor. Arthritis Rheum. 2001;44:1761-1767.
104. Crompton R, Clifton VL, Bisits AT, Read MA, Smith R, Wright IM. Corticotropin-releasing hormone causes vasodilation in human skin via mast cell-dependent pathways. J Clin Endocrinol Metab. 2003;88:5427-5432.
105. Kaneko K, Kawana S, Arai K, Shibasaki T. Corticotropin-releasing factor receptor type 1 is involved in the stress-induced exacerbation of chronic contact dermatitis in rats. Exp Dermatol. 2003;12:47-52.
106. Theodosakis J, Adderly BD, Fox B. The Arthritis Cure: The Medical Miracle That Can Halt, Reverse, and May Even Cure Osteoarthritis. New York, NY: St Martin's Griffin; 1996.
107. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000;283:1469-1475.
108. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357:251-256.
109. Hagen LE, Schneider R, Stephens D, Modrusan D, Feldman BM. Use of complementary and alternative medicine by pediatric rheumatology patients. Arthritis Rheum. 2003;49:3-6.
110. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833-1840.
111. Weisman MH, Paulus HE, Russak SM, et al. Development of a new instrument for rheumatoid arthritis: the Cedars-Sinai Health-Related Quality of Life instrument (CSHQ-RA). Arthritis Rheum. 2003;49:78-84.
112. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162:2113-2123.
113. Muller-Fassbender H, Bach GL, Haase W, Rovati LC, Setnikar I. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage. 1994;2:61-69.
114. McAlindon T. Why are clinical trials of glucosamine no longer uniformly positive? Rheum Dis Clin North Am. 2003;29:789-801.
115. Yu JG, Boies SM, Olefsky JM, The effect of oral glucosamine sulfate on insulin sensitivity in human subjects. Diabetes Care. 2003;26:1941-1942.
116. Theoharides TC, Sieghart W, Greengard P, Douglas WW. Anti-allergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. Science. 1980;207:80-82.
117. Kempuraj D, Huang M, Kandere-Grzybowska K, et al. Azelastine inhibits secretion of IL-6, TNF-α and IL-8 as well as NF-κB activation and intracellular calcium ion levels in normal human mast cells. Int Arch Allergy Immunol. 2003;132:231-239.
118. Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis: the role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am. 1999;25:379-395.
119. McAlindon T. Glucosamine and chondroitin for osteoarthritis? Bull Rheum Dis. 2001;50:1-4.
120. Duensing TD, Wing JS, vanPutten JP. Sulfated polysaccharide-directed recruitment of mammalian host proteins: a novel strategy in microbial pathogenesis. Infect Immun. 1999;67:4463-4468.
121. Rostand KS, Esko JD. Microbial adherence to and invasion through proteoglycans [minireview]. Infect Immun. 1997;65:1- 8.
122. Hardingham TE. Structure and biosynthesis of proteoglycans. Rheumatology. 1986;10:143-183.
123. Ostrakhovitch EA, Afanas'ev IB. Oxidative stress in rheumatoid arthritis leukocytes: suppression by rutin and other anti-oxidants and chelators. Biochem Pharmacol. 2001;62:743-746.
124. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349:1628-1635.
125. Boon H, Westlake K, Stewart M, et al. Use of complementary/ alternative medicine by men diagnosed with prostate cancer: prevalence and characteristics. Urology. 2003;62:849-853.
126. Hanno PM, Levin RM, Monson FC, et al. Diagnosis of interstitial cystitis. J Urol. 1990;143:278-281.
127. Messing EM, Stamey TA. Interstitial cystitis: early diagnosis, pathology and treatment. Urology. 1978;12:381-392.
128. Sant GR. Interstitial cystitis: pathophysiology, clinical evaluation and treatment. Urol Ann. 1989;3:172-196.
129. Theoharides TC, Flaris N, Cronin CT, Ucci A, Meares E. Mast cell activation in sterile bladder and prostate inflammation. Int Arch Allergy Appl Immunol. 1990;92:281-286.
130. Theoharides TC, Pang X, Letourneau R, Sant R. Interstitial cystitis: a neuroimmunoendocrine disorder. Ann NY Acad Sci. 1998;840:619-634.
131. Tomaszewski JE, Landis JR, Russack V, et al. Biopsy features are associated with primary symptoms in interstitial cystitis: results from the interstitial cystitis database study. Urology. 2001;57(Suppl):67-81.
132. Curhan GC, Speizer FE, Hunter DJ, Curhan SG, Stampfer MJ. Epidemiology of interstitial cystitis: a population based study. J Urol. 1999;161:549-552.
133. Alagiri M, Chottiner S, Ratner V, Slade D, Hanno PM. Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. Urology. 1997;49(Suppl):52-57.
134. Koziol JA, Clark DC, Gittes RF, Tan EM. The natural history of interstitial cystitis: a survey of 374 patients. J Urol. 1993;149:465-469.
135. Parsons CL, Dell J, Stanford EJ, et al. Increased prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity. Urology. 2002;60:573-578.
136. Lukban JC, Whitmore KE, Sant GR. Current management of interstitial cystitis. Urol Clin North Am. 2002;29:649-660.
137. Rovner E, Propert KJ, Brensinger C, et al. Treatments used in women with interstitial cystitis: the interstitial cystitis data base (ICDB) study experience. Urology. 2000;56:940-945.
138. Spanos C, Pang X, Ligris K, et al. Stress-induced bladder mast cell activation: implications for interstitial cystitis. J Urol. 1997;157:669-672.
139. Castagliuolo I, Wershil BK, Karalis K, Pasha A, Nikulasson ST, Pothoulakis C. Colonic mucin release in response to immobilization stress is mast cell dependent. Am J Physiol. 1998;274:G1094-G1100.
140. Theoharides TC, Letourneau R, Patra P, et al. Stress-induced rat intestinal mast cell intragranular activation and inhibitory effect of sulfated proteoglycans. Dig Dis Sci. 1999;44:87S-93S.
141. Chiang G, Patra P, Letourneau R, et al. Pentosanpolysulfate (Elmiron) inhibits mast cell histamine secretion and intracellular calcium ion levels: an alternative explanation of its beneficial effect in interstitial cystitis. J Urol. 2000;164:2119-2125.
142. Theoharides TC, Kops SK, Bondy PK, Askenase PW. Differential release of serotonin without comparable histamine under diverse conditions in the rat mast cell. Biochem Pharmacol. 1985;34:1389-1398.
143. Minogiannis P, El-Mansoury M, Betances JA, Sant GR, Theoharides TC. Hydroxyzine inhibits neurogenic bladder mast cell activation. Int J Immunopharmacol. 1998;20:553-563.
144. Sant GR, Propert KJ, Hanno PM, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003;170:810-815.
145. Katske F, Shoskes DA, Sender M, Poliakin R, Gagliano K, Rajfer J. Treatment of interstitial cystitis with a quercetin supplement. Tech Urol. 2001;7:44-46.
146. Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology. 1999;54:960-963.
147. Theoharides TC, Sant GR. An open label clinical study of CystoProtek in interstitial cystitis. Int J Immunopathol Pharmacol. In press.
148. Zuckerman GB, Bielory L. Complementary and alternative medicine herbal therapies for atopic disorders. Am J Med. 2002;113:47S-51S.
149. Mittman P. Randomized, double-blind study of freeze-dried Urtica dioica in the treatment of allergic rhinitis. Planta Med. 1990;56:44-47.
150. Thomet OA, Schapowal A, Heinisch IV, Wiesmann UN, Simon HU. Anti-inflammatory activity of an extract of Petasites hybridus in allergic rhinitis. Int Immunopharmacol. 2002;2:997-1006.
151. Thomet OA, Wiesmann UN, Schapowal A, Bizer C, Simon HU. Role of petasin in the potential anti-inflammatory activity of a plant extract of petasites hybridus. Biochem Pharmacol. 2001;61:1041-1047.
152. Bickel D, Roder T, Bestmann HJ, Brune K. Identification and characterization of inhibitors of peptido-leukotriene-synthesis from Petasites hybridus. Planta Med. 1994;60:318-322.
153. Thomet OA, Simon HU. Petasins in the treatment of allergic diseases: results of preclinical and clinical studies. Int Arch Allergy Immunol. 2002;129:108-112.
154. Schapowal A. Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis. BMJ. 2002;324:144-146.
155. Jerusalem E. Systemische Behandlung allergischer Erkrankungen mit einem Naturstoffraparat gute erfolge bei Rhinitis allergica, Kontaktdermatitis, Urticaria und anderen allergisch bedingten Erkrankungen (Praxisstudie ermsech). Der Allgemeinarzt. 1989;11:106-116.
156. Melchart D, Linde K, Fischer P, Kaesmayr J. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2000;CD000530.
157. Melchart D, Linde K, Worku F, et al. Results of five randomized studies on the immunomodulatory activity of preparations of Echinacea. J Altern Complement Med. 1995;1:145-160.
158. Ikawati Z, Wahyuono S, Maeyama K. Screening of several Indonesian medicinal plants for their inhibitory effect on histamine release from RBL-2H3 cells. J Ethnopharmacol. 2001;75:249-256.